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ABSTRACT 
Background: Retinoblastoma is the most common primary intraocular malignancy in children, although it is a rare neural 
retinal tumor. Improving the quality of life is the next goal after the primary medical goal of life preservation. The genotype-
phenotype correlation may vary with the progression of retinoblastoma. Expressivity is determined by different RB1 gene 
mutations among individuals. Herein, we share our experience on the evaluation of the long-term progression of 
retinoblastoma, its treatment consequences, its impact on the quality of life, and how the underlying genotypes are related 
to the phenotypes. We provide a review of the relevant literature and present a case of a sporadic heritable bilateral 
retinoblastoma. 
Case Presentation: We report the outcomes of a 28-year follow-up of a female diagnosed with an infantile disease. The 
patient’s best eye, according to the tumor classification and genetic results, was treated conservatively whereas the worst eye 
was enucleated. On re-examinations, she had complications of the treatment she received. Therefore, another intervention 
was administered for several years. The patient’s pathogenic variant and RB1 gene mutational inactivation were 
predispositions to the recurrence of the tumor and non-ocular primary malignancy. Nevertheless, the disease had no 
progression. The patient is stable despite her type of retinoblastoma, which is the sporadic heritable bilateral form. 
Conclusions: Each phenotype of bilateral retinoblastoma varies in progression. The nature of the genetic mutation may 
determine its expressivity. It is of great significance to individualize every decision. In each case, the sequelae of the disease 
and treatment-induced complications may have an impact on the quality of the patient’s life.  
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INTRODUCTION 
Retinoblastoma (Rb) is a rare neural retinal tumor (–1:15-
20.000 live births), probably arising from the cone 
precursor cells. It is the most common primary intraocular 
malignancy in children. The proportion of pediatric 
cancers is 17% in neonates [1], 13% in infants [2], and 6% 
and 3% during the 5th and 15th years, respectively [3, 4]. 
The genetic mechanism underlying Rb represent an 
interesting example of the genetic underpinning of 
cancer. It correlates with mutations to the tumor 
suppressor gene RB1, and in respect to the type of the first 
mutation it can result in distinct presentations. These 
include hereditary germline or non-hereditary somatic Rb 
based on family history, laterality at presentation, and 
current genetic tests [5]. Continuous progress in diagnosis 
and treatment methods has contributed to the 5-year 
disease-free survival rate of Rb, which is the highest rate 
for a pediatric cancer. The preservation of ocular function 
and vision seems to be achieved in more than 97% of high-
income countries and specialized centers [4, 6, 7]. 
Nevertheless, survival rates are much lower in the 
developing world, as was the case within the previous 
decades. Of bilaterally affected children, 96% had their 
worst eye enucleated during the irradiation era, with total 
blindness due to treatment failure occurring in 25-29% [8, 
9]; 64-66% had their worst eye enucleated during the era 
of systemic chemotherapy, with total blindness in 2-6% [9, 
10]; less than 8%  had their worst eye enucleated during 
the targeted chemotherapy era in cases with advanced 
disease [11]. The approach to treatment management 
may be highly individualized, and a collaboration of 
specialists is of great significance.  
Here, we present a case of a woman with a sporadic 
heritable bilateral Rb diagnosed during infancy and 
followed up for 28 years. We aim to discuss the type of Rb 
and evaluate its long-term impact on the quality of life. 
We will also investigate the mutational pathogenic 
variability and penetrance of the disease and the 
relationship between its underlying genotypes and its 
phenotypes. We further highlight the predispositions to 
an increased risk of recurrence or second primary 
malignancies and the available therapeutic modalities.  
CASE PRESENTATION 
A seven-month-old female infant was presented to the 
pediatrician due to the clinical presentation of gaze-
dependent leukocoria. The sign was identified during 
different gazes in the left eye, while it was intermittent 
and not visible during a straight gaze but only from the 
temporal side of the right eye. Therefore, the patient was 
immediately referred to an ophthalmologist and, in turn, 
a pediatric oncologist, she was subsequently diagnosed 
with infantile bilateral Rb. 
Tumor classification was used to evaluate the extent of 
the disease and determine the treatment approach, 
prognosis of eye preservation, and patient survival. The 
tumor staging was based on the usual classification 
systems that have been used for almost three decades 
(1992), as follows. According to the Reese and Ellsworth 
classification, the right eye was classified as IVa (multiple 
tumors larger than 10 disc diameter [DD] – unfavorable for 
preserving the eye), and the left eye was classified as Va 
(tumors involving more than half of the retina – very 
unfavorable for preserving the eye) [12]. According to the 
Essen classification, the right eye was classified as IIa 
(moderate-sized tumors of 8-10 DD, if not belonging to 
groups III-V for other reasons – favorable likelihood of 
globe salvage), and the left eye was classified as IVb (large 
tumors adjacent to or overlapping the optic disc – 
unfavorable likelihood of globe salvage) [13]. Magnetic 
resonance imaging (MRI) of the brain and orbits ruled out 
any extraocular or central nervous system involvement. 
Further examination revealed no metastatic spread to the 
regional nodes, lungs, brain, and bones. 
Genetic testing indicated a mutation in the tumor 
suppressor gene RB1 (NM_000321.2) and c.1959dupA 
(p.Val654Serfs*14), which were pathogenic. Genetic 
examinations of the patient’s family members were 
performed. Relatives with the disease, heterozygosity for 
an oncogenic RB1 allele, or the clinical presence of Rb-
associated eye lesions, such as retinomas, calcified retinal 
scars, or phthisis, were not found. Consequently, our case 
resulted from a de novo prezygotic germline mutation in 
the gametes of one of the healthy parents of the patient, 
which led to the mutational inactivation of the RB1 gene. 
Thus, the Rb was classified as a sporadic/isolated heritable 
form. The therapeutic approach to the disease was 
demonstrated in a specialized center in Hospital 
Ophtalmique Jules Gonin, Lausanne, Switzerland, on 
October 30, 1992. The patient received the appropriate 
treatments according to the protocol at that time. 
Conservative treatment was administered in the right eye, 
which was the best eye. It included brachytherapy with a 
radioactive cobalt plaque (15 mm) and simultaneous 
cryotherapy for the pre-equatorial mass applied to the 
nasal side of the retina at the location of the tumor. 
Enucleation was performed in the left eye, which was the 
worst eye at diagnosis. Histological examination indicated 
a moderately differentiated type of Rb. It demonstrated 
an exophytic growth pattern towards the subretinal 
space, which led to retinal detachment. There was no 
tumor invasion of the optic nerve, choroid, or vitreous 
body. The ophthalmological follow-up of our patient lasted 
for 28 years. Within the first year of her life, immediate 
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supplementary treatment was administered because of a 
suspicious whitish region within the equatorial region. 
Subsequent examinations showed treatment-induced 
complications that lasted for several years, and they were 
mainly associated with the irradiated part of the retina; they 
consisted of radiation-related sectoral maculopathy and 
retinopathy, including proliferative neovascularization with 
consequent vitreous hemorrhage. A subcapsular cataract 
formation was observed. The dysfunctions of the lacrimal 
gland and nasolacrimal duct were observed after the initial 
treatment. Therefore, the patient underwent further topical 
and systemic therapy. These therapeutic modalities included 
cryotherapy and xenon photocoagulation, and they were 
repeated based on the outcomes. The multiple topical 
interventions facilitated a recession and the inactivation of 
the retinopathy, and chorioretinal atrophy occurred within 
the treated area. A subcapsular cataract obstructing the 
optical axis, which reduced the visual acuity, interfered with 
the examination of the fundus, and negatively impacted the 
quality of life for the patient, was observed. Because Rb 
active lesions were not suspected, cataract surgery was 
performed in Hospital Ophtalmique Jules Gonin, Lausanne, 
Switzerland on  July 03, 2006 during the disease-free follow-
up at the age of 14 years according to the protocol. She 
underwent phacoemulsification with posterior chamber 
intraocular lens implantation under general anesthesia. The 
posterior capsule remained intact. The postoperative 
treatment regimens included antibiotics, corticosteroids, and 
non-steroidal anti-inflammatory medications for two 
months. The posterior capsule, which was left intact, 
eventually became opacified, and she underwent 
neodymium (Nd): YAG laser capsulotomy approximately a 
year later. Some weeks later, her vision decreased due to 
cystoid macular edema compatible with the Irvine-Gass 
syndrome. Optical coherence tomography (OCT) revealed 
cystoid macular edema, and it confirmed the diagnosis 
(Figure 1). There was an intermittent relapse within the 
following two years, despite the topical and systemic 
pharmaceutical treatment. She received long-term 
treatment with high-dose oral acetazolamide: 250mg 
acetazolamide tablets three times daily for 12 months, 
followed by 125 mg three times daily for 8 months and 125 
mg twice daily for the last 8 months. Potassium gluconate 
was also administered to prevent the potential side effects of 
the medication. Our patient suffered from adverse effects of 
the ongoing therapy, which mainly included recurrent 
episodes of headache and dizziness accompanied by a feeling 
of depression that affected her quality of life. There were also 
intermittent anterior chamber angle closure and intraocular 
pressure elevation, which were managed accordingly. The 
treatment-induced complications lasted till she was 17 years 
old.  
After the recession of the complications, the patient was 
stable until the recent regular ophthalmological 
examination. On examination of the right eye, the anterior 
segment was quiescent; a dilated vascular network 
located nasally corresponded to the irradiated tumor 
area. The posterior segment was also quiescent, with 
chorioretinal atrophy corresponding to the treated area 
(Figure 2). The confrontational test showed a limitation of 
the temporal visual field, although the patient did not 
cooperate during automated visual field examination. The 
best-corrected distance visual acuity was 20/25 on the 
Snellen chart. In the left socket, there was an esthetically 





Figure 1: Right-eye Optical Coherence Tomography (OCT) 
examination revealed cystoid macular edema compatible with 
Irvine-Gass syndrome. The patient was treated with oral 
acetazolamide at the age of 15 years (a). The cystic spaces 
gradually diminished after two years of treatment (b). No 
evidence of cystic spaces was observed three years after the 
diagnosis (c).  
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Figure 2: Anterior and posterior segment examination of the 
right eye at the age of 25 years. The dilated conjunctival vascular 
network in the nasal region of the anterior segment, 
corresponding to the irradiated tumor area, is notable (a). 
Radiation-related sectoral maculopathy (b) and retinopathy (c) 
can be observed in the color fundus photos. The nasal 
chorioretinal atrophy corresponds to the treated area. 
Our patient and her family have been advised on the 
estimated risks of recurrence of the malignancy and possible 
risk of non-ocular or non-retinoblastoma malignancies later 
in life. They have been educated on the common signs of 
these conditions, to facilitate the prompt report of any 
suspicious symptoms, complimentary screening, and early 
diagnosis. The patient was further advised on the possibility 
of tumor development in her offspring and her options for 
avoiding the transmission. Table 1 summarizes the studies 
used for retinoblastoma management. Our case 
presentation was conducted in accordance with the ethical 
standards declared in the Declaration of Helsinki and was 
approved by the institutional review board. Data were 
collected to ensure Ethics Committee approval. 
Furthremore, we received a signed informed consent from 
the patient. 
DISCUSSION  
Our patient was diagnosed with the sporadic heritable 
bilateral form of Rb during infancy. Following the tumor 
classification and genetic results, she underwent 
conservative treatment in one eye and enucleation in the 
other. The classification staging systems and therapeutic 
modalities that were used may be considered obsolete in 
current practice. Our patient underwent a long-term follow-
up for 28 years. Although she presented with treatment-
induced complications, treatment was continued for several 
years, and she maintained a satisfactory visual acuity. 
Genetic analysis revealed a pathogenic variant and RB1 gene 
mutational inactivation that predisposed her to tumor 
recurrence and a non-ocular primary malignancy. However, 
there has been no progression of the disease until today. Our 
patient was stable despite the type of Rb. 
Rb may be metastatic and potentially lethal if left untreated. 
The therapeutic approach aims to preserve life primarily; 
ocular survival, visual preservation, and quality of life are 
secondary targets [14]. The diagnosis, treatment, and 
monitoring of the patient involved the collaboration 
between various specialists, including ophthalmologists, 
pediatric oncologists, geneticists, related health personnel, 
and parents. It is of great significance that treatment is 
individualized [14]. Based on the two-hit hypothesis by 
Knudson, hereditary germline Rb is caused by two mutational 
events that target a gene on chromosome 13q [15, 16]. RB1 
was identified as the target of the mutational inactivation. 
The alterations are targeted at two alleles of the autosomal 
gene locus, and bi-allelic inactivation may be sufficient for Rb 
genesis [17, 18]. Although in some cases, tumors may 
develop with biallelic RB1 loss as the sole genomic alteration, 
recent studies have demonstrated recurrent chromosomal 
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Table. Studies on retinoblastoma (Rb) management: gene mutational variability, potential risk of further malignancies, and treatment modalities. 
First author, publication date, and 
Study design 
Short description Outcomes of the study 
Munier FL. et al (2019), [14] 
Review 
Description of the conservative management of 
retinoblastoma with considerations of potential 
metastasis, retinoblastoma genesis, mutational 
variabilities, imaging diagnostic modalities, disease and 
treatment-induced complications, new therapeutic 
targets, and concepts.  
The advent of new therapeutic techniques 
facilitates eye salvage and a better quality of life.    
Corson TW. et al (2007), [19]  
Review 
Mutational events and loss of both alleles in the tumor 
suppressor gene RB1 are necessary for the initiation and 
progression of retinoblastoma. The association between 
genomic changes and clinical parameters should be 
considered. Genes showing genomic changes are more 
stable markers and potential therapeutic targets than 
genes that are simply differentially expressed.  
Genomic changes in a molecular cytogenetic 
pathway are critical in the development of 
retinoblastoma. 
The evaluation of cancer genes has diagnostic, 
prognostic, and therapeutic implications.  
Lohmann DR. et al (2004), [21] 
Review 
Analysis of genotype-phenotype correlation and variability 
in expression of features.  
The relationship between genotype and phenotypic 
expression in hereditary retinoblastoma varies. 
Hung CC. et al (2011), [22] 
Study of 30 individuals from one 
family  
Assessment of a mutation of the RB1 gene associated with 
low penetrance retinoblastoma within a family. 
Evaluation of various mutations may indicate the 
penetrance of the disease. 
Taylor M. et al (2007), [23] 
Study of 50 pedigrees (165 carriers 
of RB1 mutation) 
A study of patients with a family history of retinoblastoma 
and the spectrum of RB1 germline mutations. 
Description of genotype-phenotype correlations in 
hereditary familial retinoblastoma. Modifiable 
factors may affect the pRB pathway regulation. 
Abramson DH. et al (2001), [24] 
Study of 1,506 patients (211 
second-tumor patients) 
Incidence, timing, pattern, distribution, and survival as a 
result of more non-ocular primary tumors in survivors of 
retinoblastoma. 
Retinoblastoma patients who have survived a 
second malignancy are at higher risk of additional 
tumors. The locations and expected age at which 
new tumors develop are consistent with the 
patterns from the previous condition of the patient. 
Kleinerman RA. et al (2012) , [25]  
Study of 1,852 1-year survivors of 
retinoblastoma 
Assessment of the variation of the second cancer risk with 
the family history of retinoblastoma. Evaluation of the risk 
of second cancer in long-term survivors of retinoblastoma 
according to the classification of germline mutation and 
based on family history of Rb and laterality. 
An inherited germline mutation with bilateral 
disease is associated with a greater predisposition 
to a second malignancy compared with the de novo 
germline mutation. Shared genetic alterations 
should be considered.   
 
 
Based on the timing of the two mutational events required 
to alter both RB1 alleles, Rb is divided into heritable and 
non-heritable forms. Thus, Rb can be classified into four 
genetic forms. These include the inherited 
heritable/familiar form, isolated heritable form, mosaic 
form, and the non-heritable somatic form [5]. The 
heritable form, either familiar or isolated, is caused by 
germline genetic alterations. Typically, both oncogenic 
alleles identified from de novo mutations or familiar Rb 
with complete penetrance result in absent or disrupted 
pRB protein functions [21]. Loss-of-function variants in 
RB1 are known to be pathogenic. Individuals with 
heritable forms are heterozygous for an oncogenic RB1 
allele throughout their body; thus, the first mutation is 
present in all cells. An additional genetic alteration 
targeting the other RB1 allele during retinal development 
is the second mutation that may initiate Rb genesis. 
Expressivity varies with the type of mutation at the first or 
the second allele. The nature of the mutation at the first 
allele determines the complete or incomplete penetrance. 
The number of mutations in the second allele affects the 
tumor extent. In sporadic heritable Rb, the expression 
may or may not be attenuated, depending on the first 
mutation. Cases with de novo mutations result in 
oncogenic variants that are indistinguishable from familiar 
cases with complete penetrance (full expressivity). The 
majority of patients with bilateral Rb (95%) have germline 
RB1 mutations and are heterozygous for an oncogenic RB1 
allele that leads to pRB protein function loss, while the 
remaining 5 % of the cases may be attributed to low-level 
mosaicism [21]. Due to its high penetrance, heritable Rb 
may be highly expressive. However, in some cases, low 
penetrance of RB1 mutations has been reported, resulting 
in reduced expressivity. Incomplete penetrance is 
associated with genetic alterations that probably retain 
some of the pRB protein functions or affect the regulation 
of transcription of this gene [21]. Speculative explanations 
of the penetrance of Rb suggest that the incidence of 
somatic mutation, combination, and non-disjunction 
affect the retention of the residual normal allele in all 
retinal cells in carriers of germline mutations [22, 23, 26, 
27]. Patients with a genomic 13q14 deletion have reduced 
expressivity, and those with large interstitial 13q deletions 
show incomplete developmental phenotypes [28].  
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Although the underlying molecular mechanisms in cases 
of heritable Rb with low penetrance and variable 
expressivity are not well understood, mutation 
identification permits a more accurate estimation of the 
outcomes. The investigations of the mechanisms 
underlying the phenotypic expressions may include the 
investigation of variant RB1 alleles associated with a low 
penetrance phenotype. The clinical assessment and 
molecular analysis indicate the phenotype and 
penetrance of RB1 mutations in individuals. Research has 
shown that variable phenotypes can result from several 
factors, including modifier genes, allelic variation, and 
complex genetic and environmental interactions. Genetic 
epistasis is hypothesized to be an important factor in the 
development and progression of cancer and is widespread 
among cancer genes. Cancer is a consequence of the 
accumulation of mutations that may act epistatically 
during the disease. However, the determination of the 
combinations of genetic alterations that may interact to 
produce a specific phenotype remains a challenge. The 
genotype at one locus may affect the expression of alleles 
at another locus, and this interaction may occur between 
non-allelic genes. By assessing gene pairs and evaluating 
mutational profiling, it has been indicated that genetic 
interaction mapping may facilitate the personalization of 
treatment and the prediction of outcomes [29]. In our 
case, the sequence change that was detected in the RB1 
gene is known to create a premature translational stop 
signal (p.Val654Serfs*14). This variant has been reported 
in individuals with bilateral Rb in the Leiden Open-source 
Variation Database [30], and it has been classified as 
pathogenic. This is expected to result in an absent or 
disrupted protein product. Evaluating the phenotype, we 
consider that expressivity is associated with the 
penetrance of the germline mutation of the RB1 gene. 
Epistasis with protective genes may have occurred during 
the disease. The genotype-phenotype correlation was 
determined based on the specific mutation, and it may be 
used to differentiate individuals with various mutations 
[21]. 
In cases with a positive family history of the disease, early 
screening for Rb is recommended. Before the use of 
modern imaging techniques and genetic testing, 
diagnostic screening was performed postnatally with 
indirect ophthalmoscopy [31]. Currently, for families with 
a known mutation, RB1 mutational testing with DNA 
analysis may be carried prenatally during pregnancy using 
chorionic villus sampling or amniocentesis [32]. Genetic 
counseling depends on the presentation and the type of 
Rb. Genetic alterations, allelic heterogeneity, variability in 
penetrance, and heritability of the background may 
dictate separate approaches to counseling [33]. In isolated 
heritable cases, the recurrence risk for siblings is 2% and 
even lower in other family members. The overall 
probability of transmission in the offspring of a patient in 
these cases is less than 50% due to possible somatic 
mutational mosaicism [34]. In our case, genetic counseling 
was provided to the parents, and genetic examinations 
were carried out. Heterozygosity or mutational 
inactivation of an oncogenic RB1 allele was not indicated; 
thus, the case was considered to be sporadically heritable. 
Our patient has been advised on the risk of tumor 
development in her offspring and her options for avoiding 
transmission by prenatal and preimplantation diagnosis. 
The screening schedule that was proposed in the current 
case for her future family planning was as follows: DNA 
extraction for mutational testing either by 
preimplantation genetic diagnosis or chorionic villus 
sampling at the end of the first trimester or amniocentesis 
during the second trimester of pregnancy. She was 
informed of the potential miscarriage risk for both 
procedures. Our patient was counseled for her condition 
during the early years of her diagnosis. She was informed 
of the prospects during her follow-up and advised by 
various specialists, such as geneticists, ophthalmologists, 
oncologists, and psychiatrists.   
Due to the mutations in all cells in heritable cases, the 
majority of children develop bilateral and multifocal 
tumors usually within the first years of life, mainly during 
the first stage. The prevalence of sporadic Rb in these 
cases is 10% during the neonatal period [35]; it is generally 
diagnosed under 3 years, rare after 8 years, and typically 
not found after the age of 15 years [36-38]. The size of a 
gene deletion tends to correlate with the aggressiveness 
of Rb. Rb patients carrying a germline RB1 mutation have 
a lifetime risk of developing various types of primary 
malignancies, which further increases after external beam 
irradiation and chemotherapy [24, 39]. This condition is 
associated with a predisposition to non-ocular tumors, 
such as pinealoblastoma, osteosarcoma, soft tissue 
sarcoma, and melanoma. The prevalence of secondary 
malignancies differs among various age groups [40-42]. 
Additionally, the carriers of inherited germline mutations 
have a slightly higher risk than those with a de novo 
germline mutation [25], which may be attributed to 
reduced penetrance or mosaicism [43]; in all these cases, 
primary nonretinoblastoma neoplasms may be the cause 
of mortality. In our case, the patient had no recurrence of 
malignancy until her last regular examination. 
Complimentary screening was performed, as indicated. 
The patient and family were educated on the increased 
risk and common signs of non-ocular or 
nonretinoblastoma malignancies which may develop in 
retinoblastoma survivor in later years.. Although the 
patient’s type of Rb predisposed her to secondary 
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neoplasms, she did not develop any during her 28-year 
follow-up.  
Classification systems provide a universal basis for cancer 
management, particularly in Rb. The diagnosis is clinical 
and there is no need for biopsy. In our case, the tumor 
staging was based on two separate classification systems 
introduced three decades ago (1992), although they are 
not currently used. The Reese and Ellsworth classification 
staging system grouped intraocular Rb into five for 
predicting eye survival in response to external beam 
radiotherapy for the affected eye, and not the likelihood 
of survival. It was the first system that considered the 
intraocular extent of the disease and was introduced in 
the 1960s [12, 44]. The Essen classification presented by 
Hopping was formulated based on newer evolving 
treatment modalities and showed a favorable correlation 
with globe salvage. This classification is difficult to apply in 
clinical practice and was therefore not used extensively 
[13]. The new systems are important for risk stratification 
and decision making and predictions of treatment success, 
including eye salvage and visual acuity preservation, and 
the development of a staging system to incorporate 
intraocular and extraocular diseases. The recently 
introduced Tumor, Node, Metastasis, and Heritability 
(TNMH) classification has been proposed to more 
accurately predict eye salvage, metastasis, and patient 
survival based on the intraocular, extraocular, and 
pathological manifestations of the disease and the 
hereditary status. It is likely to become the gold standard 
reference in the future [45]. It may provide a common 
foundation for evaluating the extent of disease and 
facilitate a more accurate and safe approach to patient 
management. The classification used to evaluate the 
disease extent and determine the treatment management 
and prognostication in our case differs from 
contemporary assessment systems. Our patient received 
the indicated treatment for almost three decades based 
on these systems. 
New therapeutic modalities for the management of Rb 
have emerged over the last 20 years. Our patient received 
the indicated treatment based on the classification staging 
system used during that period. Until the recent 
introduction of new targeted treatment modalities, 
survival was achieved using disabling therapies. 
Historically, enucleation was the first successful 
therapeutic modality used to decrease mortality. Later, 
other methods that contributed to globe salvage, such as 
external beam radiotherapy, were used. Currently, there 
is an obvious preference for conservative treatment and 
less mutilating therapies. Conservative methods have 
been recommended as the treatment of choice for most 
cases. These include chemotherapy and intravenous or 
targeted modalities such as intra-arterial, intravitreal, or 
intracameral. The success of this technique lies in the 
selective delivery of high-dose drugs to the eye, with 
minimal systemic absorption. The well-defined genetic 
origin of Rb may indicate a potential gene therapy 
approach in the future. Research is ongoing in this field 
[14]. Nevertheless, the conservative treatment of 
retinoblastoma can be complicated by various conditions 
that are related to the disease or treatment, and if left 
untreated, they may compromise tumor management or 
globe preservation in eyes that were considered to be in 
remission [14]. In our case, the patient underwent 
enucleation of her worst eye, followed by conservative 
treatment of her best according to the protocol. In recent 
practice, this approach may be considered obsolete. She 
suffered from disease- and treatment-related 
complications for 17 years. Compared with the 
therapeutic approach used for this case, the 
contemporary treatment methodsmay be less invasive 
with a higher likelihood of eye preservation, better visual 
outcomes, and better quality of life. 
The medical goal and primary target is to treat Rb and its 
potential disease- and treatment-induced complications. 
However, the overall quality of life and psychosocial 
consequences are particularly important. The risks of 
recurrence, non-ocular malignancies, further loss of 
vision, or having an affected offspring may negatively 
affect patients. The quality of life should be considered in 
all cases [14]. Our patient suffered comorbidities, 
emotional instability, and reduced quality of life until the 
recession of the complications at 17 years. Our patient has 
been regularly followed-up for 28 years. Despite the type 
of Rb diagnosis, she is alive with no comorbidities and a 
satisfying quality of life. 
Since our case was initially diagnosed almost three 
decades ago, it was not possible to personally assess the 
diagnostic and therapeutic modalities that were used at 
that time. Approaches to similar cases in current practice 
differ, as contemporary methods are available. Although 
our presentation refers only to one case, our long-term 
examination and follow-up improve the understanding of 
the disease course and the various conditions that these 
patients suffer. However, our experience with the 
management and follow-up of recent cases is limited. 
Therefore, the findings from the current literature review 
provide a foundation for future prospective studies on Rb 
management. Future studies on the recent approaches to 
diagnosis and treatment and the long-term effects of Rb 
on patients’ lives would be worthwhile. Further research 
should be carried out for these patients to achieve a better 
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CONCLUSION 
Rb may be life-threatening if left untreated. The progress 
of each phenotype varied. Expressivity was determined 
based on the nature of the mutations. It is important for 
observation and treatment to be individualized, and the 
therapeutic approach to every patient will be the most 
suitable. The complications of the disease and adverse 
events of the treatment that the patient is administered 
may affect the quality of life.  
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